Table 1. Participants’ characteristics.
| All | Control | ALS-FTD | ALS-CST+ | ALS-CST– | ALS-Cl | Anova/Chi-Square | ||
| N | 97 | 11 | 20 | 20 | 24 | 22 | ||
| Demographics | ||||||||
| Age | 57.9±12.7 | 51.7±16.6a | 66.7±9.9a, b, c, d | 52.9±11.5b | 58±11.5c | 57.4±11.5d | 0.003 | |
| Gender | ||||||||
| Male | 54 (56%) | 8 (73%) | 7 (35%) | 13 (65%) | 14 (58%) | 12 (55%) | 0.24 | |
| Female | 43 (44%) | 3 (27%) | 13 (65%) | 7 (35%) | 10 (42%) | 10 (45%) | ||
| Disease Characteristics | ||||||||
| ALSFRS-R | 34.6±8.4 | 30.5±7.2a | 34.9±8 | 35±8.6 | 37.2±8.7a | 0.10 | ||
| Disease Duration | 19 [12; 48] | 34 [18.8; 45] | 13 [9.5; 18.3] | 35.5 [17.8; 55] | 13 [9; 52] | |||
| Ln | 3.13±0.93 | 3.47±0.62 a,b | 2.45±0.67 a, c | 3.59±1.02 c, d | 2.92±1.02 b, d | 0.0001 | ||
| Progression Rate | 0.54 [0.24; 0.83] | 0.54 [0.34; 0.73] | 0.81 [0.53; 1.17] | 0.32 [0.16; 0.71] | 0.5 [0.19; 0.85] | |||
| Ln | −0.77±1.07 | −0.71±0.61 a | −0.05±0.83 a, b, c | −1.3±1.23 b | −0.85±1.05 c | 0.002 | ||
| EES Score | ||||||||
| 1 | 38 (45%) | 7 (35%) | 10 (50%) | 18 (75%) | 3 (15%) | 0.02 | ||
| 2 | 14 (17%) | 2 (10%) | 4 (20%) | 2 (8%) | 6 (30%) | |||
| 3 | 23 (27%) | 7 (35%) | 5 (25%) | 3 (13%) | 8 (40%) | |||
| 4 | 9 (11%) | 4 (20%) | 1 (5%) | 1 (4%) | 3 (15%) | |||
N = Number of subjects, Ln = natural log transform. EES score: 1 = defined as possible ALS, 2 = probable with laboratory support. 3 = probable and 4 = definite. Please refer to the Method section for the definition of ALS-FTD, ALS-CST+, ALS-CST–, ALS-Cl. Data are represented as N (percentage) for non categorical data, Mean ± Standard Deviation for normally distributed data, and Median [25th; 75th percentile] for non normally distributed data. Statistical analysis was performed on the natural log transform for disease duration and Disease Progression Rate to obtain normally distributed data.
Disease characteristics were not available for all subjects. Sample size for ALS-FTD/ALS-CST+/ALS-CST−/ALS-Cl are N = 17/18/23/20 for ALSFRS-R, N = 20/20/24/21 for disease duration, N = 17/18/23/19 for Disease progression and N = 20/20/24/20 for EES score.
Group connected by the same superscript letters for each outcome are significantly different (p<0.05) based on student t-test. For example, Control and ALS-FTD connected via the letter “a” are significantly different in age.